Edgewise Therapeutics to Participate in Upcoming Investor Conferences
Edgewise Therapeutics (Nasdaq: EWTX) announced management will participate in three investor conference fireside chats in November–December 2025.
Rhea-AI Summary
Edgewise Therapeutics (Nasdaq: EWTX) announced management will participate in three investor conference fireside chats in November–December 2025.
Schedule: Guggenheim Healthcare Innovation on Nov 11, 2025 at 8:30 AM ET; Piper Sandler Healthcare on Dec 2, 2025 at 2:00 PM ET; Evercore Healthcare on Dec 3, 2025 at 3:25 PM ET. Webcasts will be available on the company Events & Presentations page and accessible for replay for a limited time. Users are advised to connect several minutes early to ensure timely access to each live webcast.
Positive
- None.
Negative
- None.
Details
News Market Reaction – EWTX
On Nov 7, the day this news came out, EWTX closed 0.41% above the previous close.
Data tracked by StockTitan Argus for the Nov 7 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside chat: Tuesday, November 11, 2025 at 8:30 am ET
Piper Sandler 37th Annual Healthcare Conference
Fireside chat: Tuesday, December 2, 2025 at 2 pm ET
8th Annual Evercore Healthcare Conference
Fireside chat: Wednesday, December 3, 2025 at 3:25 pm ET
The webcasts can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company's deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. EDG-15400 is a novel cardiac sarcomere modulator for the treatment of heart failure, currently in Phase 1 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View original content to download multimedia:https://www.prnewswire.com/news-releases/edgewise-therapeutics-to-participate-in-upcoming-investor-conferences-302607782.html
SOURCE Edgewise Therapeutics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.